Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Population Council
- Target Recruit Count
- 44
- Registration Number
- NCT02236026
- Locations
- 🇺🇸
Harbor Hospital, 3001 South Hanover Street, 7th Floor, Baltimore, Maryland, United States
Alternative Antibiotic Regime in the Treatment of GAgP
- Conditions
- Interventions
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Kocaeli University
- Target Recruit Count
- 39
- Registration Number
- NCT02223702
- Locations
- 🇹🇷
Kocaeli University Faculty of Dentistry Department of Periodontology, Kocaeli, Turkey
A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02222324
Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 80
- Registration Number
- NCT02217930
- Locations
- 🇺🇸
Phase 1 unit : Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Actelion
- Target Recruit Count
- 159
- Registration Number
- NCT02206204
- Locations
- 🇺🇸
Covance Clinical Research Unit, Evansville, Indiana, United States
A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
- Conditions
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 240
- Registration Number
- NCT02193776
- Locations
- 🇿🇦
Klerksdorp Tshepong Hospital, Jouberton, Klerksdorp, South Africa
🇿🇦The Aurum Institute: Tembisa Hospital, Tembisa, Gauteng, South Africa
🇹🇿NIMR-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT02183467
Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02182310
Safety and Efficacy Study of DAV132 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Da Volterra
- Target Recruit Count
- 44
- Registration Number
- NCT02176005
- Locations
- 🇫🇷
CLINICAL INVESTIGATION CENTER (CIC), Groupe Hospitalier Bichat-Claude Bernard, Paris, France
Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.
- Conditions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT02170987
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.